Genmab — Maj 2017
-
EvaluatePharma 2022 Dara forecast $5.8bn http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=708844&isEPVantage=yes
-
Hvis man ikke har fulgt linket siger EvaluatePharma ud over peak sales på 9,4bn$ "This list of blockbusters and mega-blockbusters – drugs bringing in over $4bn per year – does not contain any surprises. In fact, J&J is fairly conservative with its predictions compared with sellside consensus forecasts."
-
Apropos tidligere om JJ's forecast. Har lyttet til præsentationen igen og set alle slides igennem. Intet sted giver JJ et forecast om "godt 4 bn" ! De opererer bare med to klasser - alm. Plus 1 bn blockbusters og mega blockbusters som bliver på mere end 4 bn !! Og Dara fremhæves. På EvaluatePharma regnes Dara peak sales til at blive JJ's absolut største produkt. Større end Imbruvica og Remicade
-
God morgen
Las os få endnu en dag med dejligt vej og et grønt marked -
Nyt combi Dara phase 3 forsøg fra Amgen. To arme med og uden Dara med Kyprolis Dex. 450 patienter!!! : https://www.clinicaltrials.gov/ct2/show/NCT03158688?term=NCT03158688&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind